Europe Opioid Use Disorder (OUD) Market Size, Share & Industry Trends Analysis Report

Europe Opioid Use Disorder (OUD) Market Size, Share & Industry Trends Analysis Report By Drug Class (Buprenorphine, Methadone and Naltrexone), By Route of Administration, By Distribution Channel, By Country and Growth Forecast, 2023 - 2030

The Europe Opioid Use Disorder (OUD) Market would witness market growth of 9.4% CAGR during the forecast period (2023-2030).

Medication-Assisted Treatment (MAT) utilizing an opioid agonist or opioid antagonist is the foundation for present therapies. MAT incorporates drugs that lessen cravings and withdrawal symptoms without causing the exhilaration that the original drug provided. MAT, which is beneficial in treating OUD and can assist some people in maintaining recovery, involves using medications in conjunction with counseling, and behavioral therapy.

The medications are generally accessible and have been made generic in many areas. However, many of these medications have recently undergone reformulations and been introduced. Reformulations and a cutting-edge mode of action are the primary concerns of pipeline medicines for treating opioid addiction. Over the forecast period, one of the main drivers of the market for opioid use disorders is anticipated to be the commercialization of these agents.

Russia has a high prevalence of drug use and has had a broad outbreak of injectable drug use for some time. With an estimated 2% of the population using drugs through a vein, a total of 18,013 persons overdosed on illegal drugs in 2020, and 7,366 died as a consequence. This represents an increase of 16% from 2019. The establishment of treatment and preventative clinics could help reduce the issue. By striking the right balance between prevention, treatment, and later social rehabilitation, these facilities want to develop an efficient treatment model that will help the market thrive.

The Germany market dominated the Europe Opioid Use Disorder (OUD) Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $371.4 million by 2030. The UK market is exhibiting a CAGR of 8.5% during (2023 - 2030). Additionally, The France market would experience a CAGR of 10.2% during (2023 - 2030).

Based on Drug Class, the market is segmented into Buprenorphine, Methadone and Naltrexone. Based on Route of Administration, the market is segmented into Parenteral and Oral. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies & Stores and Online Pharmacies. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Indivior PLC (Reckitt Benckiser Group plc), Collegium Pharmaceutical, Inc. (BioDelivery Sciences International, Inc.), Orexo AB (Orexo US, Inc.), Alkermes PLC, Titan Pharmaceuticals, Inc., Camurus AB, AstraZeneca PLC, Hikma Pharmaceuticals PLC, Mallinckrodt PLC, and Viatris, Inc.

Scope of the Study

Market Segments covered in the Report:

By Drug Class

• Buprenorphine
• Methadone
• Naltrexone

By Route of Administration

• Parenteral
• Oral

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies & Stores
• Online Pharmacies

By Country

• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe

Companies Profiled

• Indivior PLC (Reckitt Benckiser Group plc)
• Collegium Pharmaceutical, Inc. (BioDelivery Sciences International, Inc.)
• Orexo AB (Orexo US, Inc.)
• Alkermes PLC
• Titan Pharmaceuticals, Inc.
• Camurus AB
• AstraZeneca PLC
• Hikma Pharmaceuticals PLC
• Mallinckrodt PLC
• Viatris, Inc.

Unique Offerings from KBV Research

• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free